AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
p24-VLP AIDS treatment starts clinical trial in HIV+ patients. (British Bio-technology Group PLC)
British Bio-technology, Oxford, United Kingdom, announced a development in the progress of its AIDS treatment, p24-VLP.
Following a successful Phase I trial, a pilot Phase II trial started December 10, 1992, in HIV-positive patients. This is the first time that p24-VLP has been tested in HIV-positive subjects.
The pilot study is designed to test tolerability in HIV-positive subjects. The trial is being conducted at St. Mary's Hospital, Paddington, London, a United Kingdom AIDS center, under the direction of Professor Jonathan Weber.
p24-VLP, an immunotherapy, is designed to slow down or prevent the onset of AIDS in HIV-positive subjects. …
-
- p24-VLP AIDS treatment starts clinical trials in continental Europe....
-
Newspaper article from: AIDS Weekly
April 19, 1993
700+ words
-
- British Bio-technology starts first trial of its AIDS treatment, P24-VLP....
-
Newspaper article from: AIDS Weekly
August 9, 1993
700+ words
-
- Virus-like particle elicits mucosal immunity in male monkeys. (Ty-VLP)
-
Newspaper article from: AIDS Weekly
May 16, 1994
700+ words
-
- British Bio-Technology announces success of its p24-VLP immunotherapeutic in...
-
Newspaper article from: AIDS Weekly
March 9, 1992
700+ words
-
- Route of delivery may be critical.(delivery of HIV vaccine)
-
Newspaper article from: AIDS Weekly
October 9, 1995
700+ words
